The addition of a targeted agent, such as a monoclonal antibody EGFR inhibitor, has been reported to improve outcome over primary radiotherapy alone in head and neck cancers of the oropharynx, hypopharynx and larynx (44). Here, EGFR is linked to head and neck cancer.